IGNOU MST-019 Solved Assignment 2024 - Epidemiology and Clinical Trials

IGNOU MST-019 Solved Assignment 2024 | MSCAST | IGNOU

Solved By – Narendra Kr. Sharma – M.Sc (Mathematics Honors) – Delhi University

₹365.00

Get Instant Access

Access via our Android App Only

Please read the following points before ordering :

Share with your Friends
Details For MST-019 Solved Assignment

IGNOU MST-019 Assignment Question Paper 2024

mst-019-solved-assignment-2024-qp-8e24e610-06c9-4b43-84f6-a5bf6ef5ab5c

mst-019-solved-assignment-2024-qp-8e24e610-06c9-4b43-84f6-a5bf6ef5ab5c

  1. (a) In the natural history of a disease define: total preclinical phase, detectable pre-clinical phase and clinical phase. Suppose on 10 am on 25.01.2010 a disease A onset you biologically. Suppose test of the disease A can detect it exactly after completion of 1000 days of biologically onset. Suppose signs and symptoms develop exactly after completion of 1010 days of biologically onset. Suppose you consult doctor exactly after 1015 days of biologically onset of the disease. Suppose outcome the treatment is cure. What is duration of (i) total preclinical phase (ii) detectable pre-clinical phase (iii) clinical phase.
    (b) If p p p\mathrm{p}p denotes proportion and q q q\mathrm{q}q denotes odds then prove that q = p 1 − p q = p 1 − p q=(p)/(1-p)\mathrm{q}=\frac{\mathrm{p}}{1-\mathrm{p}}q=p1−p. Find the range of q q q\mathrm{q}q. If the odds of smokers in a study are 0.25 then find the proportion of smokers in the study. Assume that each subject of the study is either a smoker or non-smoker.
    (c) A trial is conducted in which some people with disease X X X\mathrm{X}X were randomly allocated into two groups. First group was advised to do some morning walk for 30 minutes and take light food each day and second group was given one injection and one 100 m g 100 m g 100mg100 \mathrm{mg}100mg tablet once a day to control disease X. The injection can cause loose motion in some cases and 100 m g 100 m g 100mg100 \mathrm{mg}100mg tablet has no side effect. At the end of two months, 90 % 90 % 90%90 \%90% of group I and 80 % 80 % 80%80 \%80% of group II had recovered from disease X X X\mathrm{X}X.
    i) What are the regimens for group I and group II in this trial?
    ii) What are the efficacies in group I and group II?
    iii) What are the safety issues in group I and group II in this trial?
  2. (a) What is the basic difference between (a) cross-sectional (b) cohort and (c) case control study designs. Explain with suitable examples of each design.
    (b) RTPCR test is applied on 300 covid patients and 200 non-covid patients. The results of the test are shown as follows.
Disease status Total
Yes ( D + ) D + (D^(+))\left(\mathrm{D}^{+}\right)(D+) No ( D − ) D − (D^(-))\left(\mathrm{D}^{-}\right)(D−)
Result of
RTPCR test
Result of RTPCR test| Result of | | :— | | RTPCR test |
 T + T + T^(+)\mathrm{T}^{+}T+ 480 40 520
T − T − T^(-)\mathrm{T}^{-}T− 120 360 480
Total 600 400 1000
Disease status Total Yes (D^(+)) No (D^(-)) “Result of RTPCR test” T^(+) 480 40 520 T^(-) 120 360 480 Total 600 400 1000| | | Disease status | | Total | | :—: | :—: | :—: | :—: | :—: | | | | Yes $\left(\mathrm{D}^{+}\right)$ | No $\left(\mathrm{D}^{-}\right)$ | | | Result of <br> RTPCR test | $\mathrm{T}^{+}$ | 480 | 40 | 520 | | | $\mathrm{T}^{-}$ | 120 | 360 | 480 | | | Total | 600 | 400 | 1000 |
What are the sensitivity and specificity of the test? Also, determine the positive and negative values of the test.
  1. (a) In usual notations you are given the following information
δ = 0.05 , π 1 = 0.75 , π 2 = 0.65 , π ¯ = 0.7 , α = 0.05 , β = 0.20 δ = 0.05 , π 1 = 0.75 , π 2 = 0.65 , π ¯ = 0.7 , α = 0.05 , β = 0.20 delta=0.05,pi_(1)=0.75,pi_(2)=0.65, bar(pi)=0.7,alpha=0.05,beta=0.20\delta=0.05, \pi_1=0.75, \pi_2=0.65, \bar{\pi}=0.7, \alpha=0.05, \beta=0.20δ=0.05,π1=0.75,π2=0.65,π¯=0.7,α=0.05,β=0.20
Find the sample size. If power of the test is 95 % 95 % 95%95 \%95% instead of 80 % 80 % 80%80 \%80%, then find new sample size.
(b) If you are told that haemoglobin ( H b ) ( H b ) (Hb)(\mathrm{Hb})(Hb) level in blood measures the iron content. The normal level in healthy people is around 15 g / d L 15 g / d L 15g//dL15 \mathrm{~g} / \mathrm{dL}15 g/dL. Most Indian women have less and some have even less than 8 g / d L 8 g / d L 8g//dL8 \mathrm{~g} / \mathrm{dL}8 g/dL. They are called anemic. Iron supplementation is given to increase this level. Suppose one supplementation increase the mean H b H b Hb\mathrm{Hb}Hb level in anemics by 3.2 g / d L g / d L g//dL\mathrm{g} / \mathrm{dL}g/dL, after one month of use and the other by 3.6 g / d L 3.6 g / d L 3.6g//dL3.6 \mathrm{~g} / \mathrm{dL}3.6 g/dL, in an equivalence trial on 500 women each. The respective SD’s of the of the increases are 0.52 and 0.72 g / d L 0.72 g / d L 0.72g//dL0.72 \mathrm{~g} / \mathrm{dL}0.72 g/dL. The doctors determine that the supplementations can be clinically equivalent if the difference between the increases by two supplementations does not exceed 0.52 g / d L 0.52 g / d L 0.52g//dL0.52 \mathrm{~g} / \mathrm{dL}0.52 g/dL. Can these two supplementations be considered clinically equivalent at 5 % 5 % 5%5 \%5% level of significance?
\(a=b\:cos\:C+c\:cos\:B\)

MST-019 Sample Solution 2024

mst-019-solved-assignment-2024-ss-8e24e610-06c9-4b43-84f6-a5bf6ef5ab5c

mst-019-solved-assignment-2024-ss-8e24e610-06c9-4b43-84f6-a5bf6ef5ab5c

  1. (a) In the natural history of a disease define: total preclinical phase, detectable pre-clinical phase and clinical phase. Suppose on 10 am on 25.01.2010 a disease A onset you biologically. Suppose test of the disease A can detect it exactly after completion of 1000 days of biologically onset. Suppose signs and symptoms develop exactly after completion of 1010 days of biologically onset. Suppose you consult doctor exactly after 1015 days of biologically onset of the disease. Suppose outcome the treatment is cure. What is duration of (i) total preclinical phase (ii) detectable pre-clinical phase (iii) clinical phase.
Answer:
In the natural history of a disease, we can define the following phases:
  1. Total Preclinical Phase: This is the period between the biological onset of the disease and the appearance of signs and symptoms. It is the time during which the disease is present in the body, but not yet clinically apparent.
  2. Detectable Pre-Clinical Phase: This is the part of the preclinical phase during which the disease is biologically present and can be detected by tests, but signs and symptoms have not yet appeared. It is the time between when the disease becomes detectable and when it becomes clinically apparent.
  3. Clinical Phase: This is the period after the signs and symptoms of the disease have appeared. It ends when the disease is either cured or results in the patient’s death.
Given the scenario:
  • Biological onset of disease A: 10 am, 25.01.2010
  • Test can detect disease A: After 1000 days of biological onset
  • Signs and symptoms appear: After 1010 days of biological onset
  • Consultation with doctor: After 1015 days of biological onset
  • Outcome of treatment: Cure
The durations of the phases are as follows:
  1. Total Preclinical Phase: From biological onset to the appearance of signs and symptoms = 1010 days
  2. Detectable Pre-Clinical Phase: From when the test can detect the disease to the appearance of signs and symptoms = 1010 days – 1000 days = 10 days
  3. Clinical Phase: From the appearance of signs and symptoms to consultation with the doctor (since the outcome is cure, we consider the clinical phase to end at consultation) = 1015 days – 1010 days = 5 days
So, the durations are:
(i) Total Preclinical Phase: 1010 days
(ii) Detectable Pre-Clinical Phase: 10 days
(iii) Clinical Phase: 5 days
\(c^2=a^2+b^2-2ab\:Cos\left(C\right)\)
Get The AppClick Here
Get Instant Access

Frequently Asked Questions (FAQs)

You can access the Complete Solution through our app, which can be downloaded using this link:

App Link 

Simply click “Install” to download and install the app, and then follow the instructions to purchase the required assignment solution. Currently, the app is only available for Android devices. We are working on making the app available for iOS in the future, but it is not currently available for iOS devices.

Yes, It is Complete Solution, a comprehensive solution to the assignments for IGNOU. 

Yes, the Complete Solution is aligned with the requirements and has been solved accordingly.

Yes, the Complete Solution is guaranteed to be error-free.The solutions are thoroughly researched and verified by subject matter experts to ensure their accuracy.

As of now, you have access to the Complete Solution for a period of 1 Year after the date of purchase, which is sufficient to complete the assignment. However, we can extend the access period upon request. You can access the solution anytime through our app.

The app provides complete solutions for all assignment questions. If you still need help, you can contact the support team for assistance at Whatsapp +91-9958288900

No, access to the educational materials is limited to one device only, where you have first logged in. Logging in on multiple devices is not allowed and may result in the revocation of access to the educational materials.

Payments can be made through various secure online payment methods available in the app.Your payment information is protected with industry-standard security measures to ensure its confidentiality and safety. You will receive a receipt for your payment through email or within the app, depending on your preference.

The instructions for formatting your assignments are detailed in the Assignment Booklet, which includes details on paper size, margins, precision, and submission requirements. It is important to strictly follow these instructions to facilitate evaluation and avoid delays.

\(cot\:\theta =\frac{cos\:\theta }{sin\:\theta }\)

Terms and Conditions

  • The educational materials provided in the app are the sole property of the app owner and are protected by copyright laws.
  • Reproduction, distribution, or sale of the educational materials without prior written consent from the app owner is strictly prohibited and may result in legal consequences.
  • Any attempt to modify, alter, or use the educational materials for commercial purposes is strictly prohibited.
  • The app owner reserves the right to revoke access to the educational materials at any time without notice for any violation of these terms and conditions.
  • The app owner is not responsible for any damages or losses resulting from the use of the educational materials.
  • The app owner reserves the right to modify these terms and conditions at any time without notice.
  • By accessing and using the app, you agree to abide by these terms and conditions.
  • Access to the educational materials is limited to one device only. Logging in to the app on multiple devices is not allowed and may result in the revocation of access to the educational materials.

Our educational materials are solely available on our website and application only. Users and students can report the dealing or selling of the copied version of our educational materials by any third party at our email address (abstract4math@gmail.com) or mobile no. (+91-9958288900).

In return, such users/students can expect free our educational materials/assignments and other benefits as a bonafide gesture which will be completely dependent upon our discretion.

Categories , Tags , , , , , , , , , ,

Related products

Our educational materials are solely available on our website and application only. Users and students can report the dealing or selling of the copied version of our educational materials by any third party at our email address (abstract4math@gmail.com) or mobile no. (+91-9958288900).

In return, such users/students can expect free our educational materials/assignments and other benefits as a bonafide gesture which will be completely dependent upon our discretion.

All Policies

Account

Company

Affiliate Program

Shipping Policy

Privacy Policy

Return Policy

Terms & Conditions

Cancellation Policy

Registration & Security

Refund Policy

Copyright & DMCA Notice

Privacy Policy

Content Copyright

Dispute Resolution

DMCA.com Protection Status

Terms of Services

Contact Us

Address: L-1/2, Uttam Nagar, Delhi, 110059
Email ID: support@abstractclasses.com 
WhatsApp No.: +91 9958288900

Online Classes available . More than 120 students joined last Month.
Contact+91-9958288900

Home

UPSC

IGNOU

My Account

Scroll to Top
Scroll to Top